Payment overview · 2025
General Payments
$1,306.12
62 reported records · 18 companies
Healthcare provider profile · identity verified
Robyn Brianna Mccarty
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OWENSBORO, KY · NPI 1932860129
Verified facts
What the public records show
CMS Open Payments records show Robyn Brianna Mccarty received $1,306.12 in general payments during 2025 across 62 reported records.
Novo Nordisk Inc accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $385.57 | 29.5% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $298.29 | 22.8% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $209.39 | 16.0% | 13 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $57.31 | 4.4% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$46.06 | 3.5% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $45.88 | 3.5% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $37.10 | 2.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.90 | 2.7% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $31.70 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.50 | 2.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.03 | 1.7% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $18.78 | 1.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.07 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.93 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.73 | 1.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.58 | 1.1% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $14.48 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.82 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,301.91 | 61 |
| Education | $4.21 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $209.39 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $197.94 | 13 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $187.63 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $158.59 | 11 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $145.53 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $97.02 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $57.31 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $46.06 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $45.88 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $36.76 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $34.90 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $31.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.40 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.40 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 182 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
182 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 80 |
| Ozempic | Semaglutide | 182 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 165 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 43 |
| Lisinopril | Lisinopril | 119 | 37 |
| Losartan Potassium | Losartan Potassium | 117 | 33 |
| Metformin Hcl | Metformin Hcl | 100 | 29 |
| Jardiance | Empagliflozin | 95 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 80 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 15 |
| Synthroid | Levothyroxine Sodium | 72 | 22 |
| Mounjaro | Tirzepatide | 71 | 17 |
| Buspirone Hcl | Buspirone Hcl | 69 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 24 |
| Omeprazole | Omeprazole | 68 | 22 |
| Trazodone Hcl | Trazodone Hcl | 67 | 18 |
| Allopurinol | Allopurinol | 66 | 15 |
| Furosemide | Furosemide | 66 | 22 |
| Trulicity | Dulaglutide | 58 | 13 |
| Celecoxib | Celecoxib | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 14 |
| Meloxicam | Meloxicam | 50 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | 12 |
| Metformin Hcl Er | Metformin Hcl | 48 | 16 |
| Farxiga | Dapagliflozin Propanediol | 47 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | 12 |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Nateglinide | Nateglinide | 44 | 14 |
| Simvastatin | Simvastatin | 43 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Tradjenta | Linagliptin | 33 | suppressed |
| Armour Thyroid | Thyroid,pork | 32 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 32 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 13 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Ondansetron Odt | Ondansetron | 19 | 13 |
| Ramipril | Ramipril | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Mupirocin | Mupirocin | 15 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,306.12 · 62 records | Novo Nordisk Inc | ACCRUFER, BREZTRI, EVENITY, FANAPT, Fibroscan, HETLIOZ, JARDIANCE, Kerendia, Korlym, LEQVIO, MINIMED 780G, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PROLIA, REPATHA, REZDIFFRA, Rybelsus, TAVNEOS, TEPEZZA, TWIIST, VOQUEZNA, Wegovy, ZAVZPRET, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error